PMID- 29039104
OWN - NLM
STAT- MEDLINE
DCOM- 20180529
LR  - 20220321
IS  - 1940-6029 (Electronic)
IS  - 1064-3745 (Linking)
VI  - 1682
DP  - 2018
TI  - In Vitro and In Vivo Methods for Analysis of Nanoparticle Potential to Induce 
      Delayed-Type Hypersensitivity Reactions.
PG  - 197-210
LID - 10.1007/978-1-4939-7352-1_17 [doi]
AB  - Delayed-type hypersensitivity (DTH) reactions are among the common reasons for 
      drug withdrawal from clinical use during the post-marketing stage. Several in 
      vivo methods have been developed to test DTH responses in animal models. They 
      include the local lymph node assay (LLNA) and local lymph node proliferation 
      assay (LLNP). While LLNA is instrumental in testing topically administered 
      formulations (e.g., creams), the LLNP was proven to be predictive of 
      drug-mediated DTH in response to small molecule pharmaceuticals. Global efforts 
      in reducing the use of research animals lead to the development of in vitro 
      models to predict test-material-mediated DTH. Two such models include analysis of 
      surface marker expression in human cell lines THP-1 and U-937. These tests are 
      known as the human cell line activation test (hCLAT) and myeloid U937 skin 
      sensitization test (MUSST or U-SENS), respectively. Here we describe experimental 
      procedures for all these methods, discuss their in vitro-in vivo correlation, and 
      suggest a strategy for applying these tests to analyze engineered nanomaterials 
      and nanotechnology-formulated drug products.
FAU - Potter, Timothy M
AU  - Potter TM
AD  - Cancer Research Technology Program, Nanotechnology Characterization Laboratory, 
      Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer 
      Research, P.O. Box B, Frederick, MD, 21702, USA.
FAU - Neun, Barry W
AU  - Neun BW
AD  - Cancer Research Technology Program, Nanotechnology Characterization Laboratory, 
      Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer 
      Research, P.O. Box B, Frederick, MD, 21702, USA.
FAU - Dobrovolskaia, Marina A
AU  - Dobrovolskaia MA
AD  - Cancer Research Technology Program, Nanotechnology Characterization Laboratory, 
      Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer 
      Research, P.O. Box B, Frederick, MD, 21702, USA. marina@mail.nih.gov.
LA  - eng
GR  - HHSN261200800001E/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Methods Mol Biol
JT  - Methods in molecular biology (Clifton, N.J.)
JID - 9214969
RN  - 0 (Allergens)
RN  - 0 (B7-2 Antigen)
RN  - EC 3.1.3.48 (Leukocyte Common Antigens)
SB  - IM
MH  - Allergens/*adverse effects
MH  - Animals
MH  - B7-2 Antigen/analysis
MH  - Cell Line
MH  - Cell Proliferation
MH  - Female
MH  - Flow Cytometry/*methods
MH  - Humans
MH  - Hypersensitivity, Delayed/*etiology
MH  - Leukocyte Common Antigens/analysis
MH  - Leukocytes/cytology
MH  - Local Lymph Node Assay
MH  - Male
MH  - Mice, Inbred BALB C
MH  - Nanoparticles/*adverse effects
MH  - Skin Tests/*methods
MH  - THP-1 Cells
OTO - NOTNLM
OT  - Allergen
OT  - Hypersensitivity
OT  - Irritant
OT  - LLNA
OT  - LLNP
OT  - Leukocyte proliferation
OT  - MUSST
OT  - Nanoparticles
OT  - Sensitizer
OT  - hCLAT
EDAT- 2017/10/19 06:00
MHDA- 2018/05/31 06:00
CRDT- 2017/10/18 06:00
PHST- 2017/10/18 06:00 [entrez]
PHST- 2017/10/19 06:00 [pubmed]
PHST- 2018/05/31 06:00 [medline]
AID - 10.1007/978-1-4939-7352-1_17 [doi]
PST - ppublish
SO  - Methods Mol Biol. 2018;1682:197-210. doi: 10.1007/978-1-4939-7352-1_17.